ArticleScientific reports2026
Development of a HiFi-LAMP assay for the detection of herpes simplex virus type 1.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Herpes simplex virus type 1 (HSV-1) has a significant impact on global public health. Developing a rapid, sensitive, and specific diagnostic assay for the detection of HSV-1 is of critical clinical significance for guiding individualized therapy and optimizing outcomes. A high-fidelity loop-mediated isothermal amplification (HiFi-LAMP) assay was developed by targeting the highly conserved region of the HSV-1 US4 gene. The sensitivity of the assay was determined using serial dilutions of standard templates, and specificity was assessed against ten common pathogens. Intra- and inter-assay reproducibility were assessed. The assay was assessed using 30 swab samples from skin lesions of patients with suspected HSV-1 infection and compared with the gold-standard real-time quantitative PCR (qPCR) assay. The HSV-1 HiFi-LAMP assay can be completed within 40 min, with a limit of detection (LOD) of 61 copies per 25 µL reaction. Specificity testing demonstrated no cross-reactivity with ten common pathogens, including HSV-2, varicella-zoster virus (VZV), Epstein–Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 6B (HHV-6B), Neisseria gonorrhoeae (NG), Treponema pallidum (TP), Ureaplasma urealyticum (UU), HIV-1, and monkeypox virus (MPXV). Intra-assay and inter-assay coefficients of variation (CVs) were below 3%, indicating high stability of the assay. Clinical evaluation with 30 clinical samples revealed a specificity of 100% and a sensitivity of 100%. The novel HSV-1 HiFi-LAMP assay does not rely on complex instrumentation and is suitable for point-of-care testing (POCT) in primary healthcare settings and resource-limited regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.